Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer
NCT ID: NCT07331519
Last Updated: 2026-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1200 participants
INTERVENTIONAL
2026-02-02
2036-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LDCT-SC-FI Low-dose CT Screening for Lung Cancer
NCT05630950
Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer
NCT03059940
Low Dose Computed Tomography for Lung Cancer Screening
NCT03084835
Implementation of Smoking Cessation Support During Lung Cancer Workup
NCT05192031
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
NCT03315910
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Smoking cessation with a smartphone application + LDCT lung cancer screening
Smartphone application
Suunta smartphone application for smoking cessation
low-dose computed tomography
Low-dose computed tomography based screening for lung cancer
Arm 2
Smoking cessation with written materials + LDCT lung cancer screening
low-dose computed tomography
Low-dose computed tomography based screening for lung cancer
Written materials for smoking cessation
Written materials for smoking cessation
Arm 3
Smoking cessation with a smartphone application without LDCT lung cancer screening
Smartphone application
Suunta smartphone application for smoking cessation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Smartphone application
Suunta smartphone application for smoking cessation
low-dose computed tomography
Low-dose computed tomography based screening for lung cancer
Written materials for smoking cessation
Written materials for smoking cessation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age between 50-74
3. Smoked ≥ 15 cigarettes/day for ≥ 25 years or smoked ≥ 10 cigarettes/day for ≥ 30 years and are active smokers (smoking during the last two weeks)
4. Access to a smartphone (iPhone or Android)
Exclusion Criteria
2. A chest CT examination less than one year before inclusion
3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
4. No access to a smartphone (iPhone or Android)
5. Participant is unwilling or unable to comply with treatment and trial instructions
6. Any condition that study investigators consider an impediment to safe trial participation
50 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Finnish Cancer Society
UNKNOWN
Oulu University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tytti Särkeälä, PhD
Role: STUDY_DIRECTOR
Finnish Cancer Society
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Hospital
Helsinki, , Finland
Oulu University Hospital
Oulu, , Finland
Tampere University Hospital
Tampere, , Finland
Turku University Hospital
Turku, , Finland
Vaasa Central Hospital
Vaasa, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jussi P Koivunen, MD, PhD
Role: primary
Maria Silvoniemi, MD, PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
Iivanainen S, Kurtti A, Wichmann V, Andersen H, Jekunen A, Kaarteenaho R, Vasankari T, Koivunen JP. Smartphone application versus written material for smoking reduction and cessation in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer: a phase II open-label randomised controlled trial. Lancet Reg Health Eur. 2024 May 25;42:100946. doi: 10.1016/j.lanepe.2024.100946. eCollection 2024 Jul.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EETMK 15/2025
Identifier Type: OTHER
Identifier Source: secondary_id
EETMK 15/2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.